Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

78.93 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
Today's Top US Stock Movers: Small-Cap Gainers and Losers ↗
Via Chartmill
Today's Top Market Movers: Silence Therapeutics Jumps 126%, CL Workshop Slides 43% ↗
Via Chartmill
News headline image
Disc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission ↗
Disc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP)... 
Via MarketBeat
Gap-Up and Gap-Down Movers for Oct. 19, 2026 ↗
Via Chartmill
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗
Via Stocktwits
Premarket Movers Oct. 19: Disc Medicine Jumps 51.62%, Rubico Falls 33.84% ↗
Via Chartmill
News headline image
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges ↗
Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company... 
Via MarketBeat
News headline image
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge ↗
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection ↗
This clinical-stage biopharmaceutical company recently had one of its treatments rejected for FDA approval. Now the company is cutting its workforce. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns ↗
The FDA said in a letter to the company published on Friday that the data submitted by the company is insufficient proof of clinical benefit for bitopertin. 
Via Stocktwits
News headline image
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run ↗
This clinical-stage biotech specializing in blood disorders reported a notable insider sale amid strong recent stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface — Wall Street Calls It An ‘Overreaction’ ↗
Stat News on Friday raised concerns for Biopertin’s expedited approval under the FDA Commissioner's National Priority Voucher program. 
Via Stocktwits
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
Disc Medicine Inc (NASDAQ:IRON) Reports Wider-Than-Expected Q3 2025 Loss Amid Pipeline Advancements ↗
Disc Medicine reported a wider Q3 2025 loss but advanced its bitopertin NDA with FDA priority review, targeting a 2025/2026 launch. 
Via Chartmill
News headline image
Top stock movements in today's session. ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings ↗
 
Via Benzinga
News headline image
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
Discover the top movers in Friday's pre-market session. ↗
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides
As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Disc Medicine (IRON) Q2 Loss Widens 109% ↗
Via The Motley Fool
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.